Physician profile
Vikram Sengupta
NPI 1740568153
$6,515.53
in general payments reported to CMS, 2019-2025
30 companies · $3,560 in 2025
The $3,560 reported for 2025 was more than what 88% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $125 · 2021: $267 · 2022: $119 · 2023: $122 · 2024: $1,041 · 2025: $3,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164 · Grant: $354 · Travel and Lodging: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.38 |
| Grant | $354.00 |
| Travel and Lodging | $204.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,024.30 | 2025 | Senza, Omnia |
| Spr Therapeutics, INC | $860.82 | 2024-2025 | Sprint Pns System |
| Abbott Laboratories | $623.23 | 2019-2025 | Proclaim, Eterna |
| Alexion Pharmaceuticals, INC. | $513.71 | 2019-2025 | Soliris, Ultomiris |
| Abbvie INC. | $478.85 | 2024-2025 | |
| Spinal Simplicity, LLC | $367.68 | 2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $314.28 | 2021-2025 | Vanta Adaptivestim |
| Horizon Therapeutics Plc | $268.04 | 2019-2020 | |
| Akcea Therapeutics, INC. | $250.00 | 2019 | |
| Intrinsic Therapeutics | $165.97 | 2025 | Barricaid Acd (Annular Closure Device) |
| Collegium Pharmaceutical, INC. | $164.21 | 2024-2025 | Xtampza |
| Intra-Sana Laboratories | $150.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $140.67 | 2024 | Spravato |
| Ucb, INC. | $134.15 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $124.99 | 2019 | |
| Amgen INC. | $118.56 | 2019 | |
| Boston Scientific Corporation | $104.60 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Lenoss Medical INC | $99.45 | 2024 | Access & Cavity Creation Kit |
| Vertex Pharmaceuticals Incorporated | $93.33 | 2024-2025 | |
| Avanos Medical | $69.47 | 2025 | |
| Tersera Therapeutics LLC | $66.38 | 2025 | Prialt |
| Scilex Pharmaceuticals INC. | $60.68 | 2024-2025 | |
| Foundation Fusion Solutions, LLC | $60.30 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $32.67 | 2024 | Iovera, Zilretta, Exparel |
| Curonix LLC | $31.59 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.25 | 2025 | Relistor |
| Averitas Pharma INC. | $20.23 | 2024 | Qutenza |
| International Rehabilitative Sciences, INC | $14.60 | 2024 | Rs 4i Plus Sequential Stimulator |
| Fidia Pharma USA INC. | $14.52 | 2024 | Triluron, Hymovis, Hyalgan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Sengupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.